Savara Inc
SVRA · XNASCIK 1160308fmd_0W9BQBVH854GACBN2VWM2A8F24制造业 · 医药制剂模板: 标准
覆盖范围: 1997年1月01日 至 2026年9月30日，共 79 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | – | 0 | 0 | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 8 | 19 | 37 | 39 | 35 | 29 | 28 | 44 | 78 | 81 |
| 销售、一般及管理费用 | 9 | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 11 | 30 | 70 | 79 | 50 | 41 | 39 | 60 | 103 | 124 |
| 营业利润 | (11) | (30) | (70) | (79) | (49) | (41) | (39) | (60) | (103) | (124) |
| 利息费用 | 0 | 1 | – | – | – | – | – | – | – | – |
| 利息及投资收益 | 0 | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (0) | (3) | 1 | 1 | (0) | (2) | 1 | 5 | 7 | 5 |
| 税前利润 | (11) | (33) | (69) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |
| 所得税费用 | (0) | (4) | (7) | – | – | – | – | – | 0 | 0 |
| 持续经营净利润 | (11) | (30) | (62) | – | – | – | – | – | (96) | (119) |
| 净利润 | (11) | (30) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |
| 归属于普通股股东的净利润 | (11) | (31) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) |